<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01109680</url>
  </required_header>
  <id_info>
    <org_study_id>MRZ 92579-1048-0</org_study_id>
    <nct_id>NCT01109680</nct_id>
  </id_info>
  <brief_title>A Single Center, Open-Label Study to Quantify Metabolites of [14C]-Neramexane in Plasma and Urine in Healthy Male Subjects</brief_title>
  <official_title>A Single Center, Open-Label Study to Quantify Metabolites of [14C]-Neramexane in Plasma and Urine in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz Pharmaceuticals GmbH</source>
  <brief_summary>
    <textblock>
      A Single Center, Open-Label Study to quantify metabolites of [14C]-Neramexane in plasma and
      urine in Healthy Male Subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolite Profiling</measure>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Metabolism of Neramexane</condition>
  <arm_group>
    <arm_group_label>14 C labelled Neramexane, capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neramexane</intervention_name>
    <description>Multiple dose Neramexane followed by single dose 14C Neramexane</description>
    <arm_group_label>14 C labelled Neramexane, capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 55 to 65 years inclusive

          -  BMI of 18-29 kg/m2 (inclusive) and a body weight of ≥50 and ≤90 kg

          -  All ethnicities, Fitzpatrick type &lt; IV (see appendix 2)

          -  Willing and able to provide written informed consent after having been informed of the
             requirements and the restrictions of the study

          -  Healthy adult male subject, who is able to read, to write and fully understand Dutch
             language

        Exclusion Criteria:

          -  History of clinically relevant allergy or known hypersensitivity to
             Neramexane/Memantine/Amantadine and their derivates

          -  Exposure to another investigational agent within the last two months before first drug
             administration

          -  Administration of radiolabeled substance or exposure to significant radiation (e.g.
             serial X-ray or CT scans etc.) within the last 12 months. X-rays or spiral CT scans of
             extremities are allowed.

        Lack of suitability for the study

          -  Any evidence of a significant cardiovascular, pulmonary, renal, hepatic,
             gastrointestinal, endocrinological, metabolic, psychiatric, neurologic or other acute
             or chronic disease

          -  Disorders or surgery of the gastrointestinal tract which may interfere with drug
             absorption or may otherwise influence the pharmacokinetics of the investigational
             medicinal products (e.g. cholecystectomy, active gastric ulcers, etc.)

          -  Clinically relevant acute or chronic infections, observed within 4 weeks before first
             drug administration

          -  History of malignancy, except basal cell carcinoma

          -  Any clinically relevant deviation in clinical or laboratory assessment as deemed by
             the investigator

          -  Abnormalities in the 12-lead ECG (at screening) which in the discretion of the
             investigator and the Merz scientific expert are clinical relevant or might affect the
             study objectives

          -  Systolic blood pressure &lt;95 mmHg or &gt;155 mmHg or diastolic blood pressure &lt; 50 mmHg or
             &gt;95 mmHg in supine position

          -  Pulse rate &lt;45 or &gt;100 beats per minute

          -  History of alcohol or drug dependence

          -  Alcohol consumption averaging a weekly intake in excess of 21 units of alcohol (one
             unit of alcohol equals a glass of beer of 300 mL, a glass of wine of 125 mL, or a
             measure of spirits of 25 mL) within the last year

          -  Regular large caffeine consumption averaging more than 6 cups of coffee and/or tea per
             day or more than 1 L of caffeine-containing beverages per day within the last year

          -  Use of any prescribed medication 4 weeks prior to the first administration of IMP
             (except paracetamol, maximum 2 g/day). Thyroid hormone substitution will be allowed)

          -  Regular use of over-the-counter drugs 4 weeks prior to the first administration of the
             IMP.

          -  Occasional use of OTC drugs (except paracetamol, maximum 2 g/day) in the 2 weeks prior
             to the first administration of the IMP

          -  Use of any food, food supplement or medication known to induce or inhibit CYP3A4 or
             other cytochrome P450 enzymes within two weeks before first drug administration e.g.
             grapefruit, St. Johns wort

          -  Consume of xanthine derivates (including caffeine) within two days before first drug
             administration

          -  Smokers or ex-smokers who have stopped for less than 6 months, and user of snuff,
             nicotine replacement chewing tobacco

          -  Blood donation more than 450 mL within 60 days before first drug administration

          -  Positive results in any of the serology tests

          -  Positive drug screen or alcohol test

          -  Subject is an employee or direct relative of an employee of the CRO or Merz
             Pharmaceuticals

          -  Lack of ability or willingness to give informed consent

          -  Lack of willingness or inability to co-operate adequately

          -  Vulnerable subjects (e.g. persons kept in detention)

          -  Anticipated non-availability for study visits/procedures
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SGS Life Science Services</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2010</study_first_submitted>
  <study_first_submitted_qc>April 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2010</study_first_posted>
  <last_update_submitted>February 7, 2011</last_update_submitted>
  <last_update_submitted_qc>February 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Dirk Garmann</name_title>
    <organization>Merz Pharmaceuticals GmbH</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

